NCT06219239 - Safety and Efficacy of the Lentiviral Vector in Gene Therapy of Beta-thalassemia Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 4, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2026

Conditions

Transfusion-dependent Beta-Thalassemia

Interventions

GENETIC

KL003 cell injection Drug Product

No conditioning regimen for transfusion of auto-HSC transduced with lentiviral vector encoding βA-T87Q-globin gene

Trial Locations (1)

RECRUITING

Institute of Hematology & Blood Diseases Hospital, Tianjin